Phase I long peptide vaccination trial in colorectal or ovarium cancer patients

We have obtained data from a phase I long peptide vaccination trial with p53 peptides in Montanide adjuvant in patients with colorectal cancer or ovarium cancer. This vaccine was well tolerated and robust p53-specific T cell responses were induced.

In the future we intend to combine the p53 vaccine with other cancer therapies such as chemotherapy.

• cell type
• T cell

• molecule type
• peptide

created over 15 years ago (16 December 2009)    last modified over 12 years ago (14 January 2013)   [ RDF ]   [ RelFinder ]